1	Multicenter analysis of immunosuppressive medications on the subsequent risk		
2	of malignancy in solid organ transplant recipients		
3			
4	Authors:		
5	Reid Shaw ¹ , Ali R. Haque ¹ , Jack Fitzsimons ¹ , Adam Hamidi ¹ , Timothy E. O'Connor ¹ ,		
6	Gregory W. Roloff ² , Bradford C. Bemiss ⁴ , Eric R. Kallwitz ⁵ , Patrick A. Hagen ⁶ , and		
7	Stephanie Berg ⁷		
8			
9	Affiliations:		
10	¹ Department of Internal Medicine, Loyola University Medical Center, Maywood, IL		
11	² Section of Hematology and Oncology, The University of Chicago, Chicago, IL		
12	³ Division of Pulmonary and Critical Care Medicine, Loyola University Medical Center,		
13	Maywood, IL		
14	⁴ Division of Hepatology, Loyola University Medical Center, Maywood, IL		
15	⁵ Division of Hematology and Oncology, Loyola University Medical Center, Maywood, IL		
16	⁶ Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA		
17			
18	Corresponding author email:		
19	reid.shaw@luhs.org		
20			
21	Word Count:		
22	Abstract: 174		

23 Main body: 2,174

- 24 Figures: 3
- 25 Supplementary figures: 5
- 26

27 Abbreviations:

SOT, solid organ transplant; EHR, electronic health record; ICD, international
classification of disease; HR, hazard ratio; CI, confidence interval; ML, machine learning;
mTOR, mammalian target of rapamycin.

31

32 Abstract:

Solid organ transplant is a curative treatment for end organ disease. However, the 33 34 immunosuppressive therapy required to prevent graft rejection increases the likelihood of 35 developing a subsequent malignancy. This retrospective cohort study from a multi-center academic hospital system investigated solid organ transplantation, immunosuppression, 36 and the risk of subsequent malignancy. Of the 5,591 patients and 6,142 transplanted 37 38 organs studied, there were 517 subsequent malignancies identified. Skin cancer was the most common type of malignancy to be diagnosed, whereas liver cancer was the first 39 malignancy to present at a median time of one-year post-transplant. Subsequent 40 malignancy was proportionally more often diagnosed in non-Hispanic White transplant 41 recipients compared to other racial groups. Heart and lung transplant recipients had 42 43 relatively higher rates of subsequent malignancy than liver and kidney transplant recipients, but this finding was not significant upon adjusting for immunosuppressive 44 medications. Multivariate cox proportional hazard analysis and random forest variable 45 46 importance calculations identified statistically significant correlations with sirolimus and

47 azathioprine and high rates of malignancy after transplant, while tacrolimus was
48 associated with low rates of post-transplant neoplasia.

49

50 **1 Introduction**

Solid organ transplant (SOT) is a curative treatment option for many patients with end-51 stage organ disease.¹ In 2021, there were more than 13,800 deceased and 6,500 living 52 donor transplants in the United States.² Although transplant-related outcomes have 53 significantly improved over time, rates of morbidity and mortality after successful 54 transplantation represent areas for clinical improvement.³ One major adverse outcome 55 after SOT is malignancy – with standardized incidence ratios of 2-4 times that of the 56 general public.^{4,5} This is due to a variety of patient,^{6,7} donor,⁸ transplant,⁹ and medication-57 related factors.8,10 58

59

Immunosuppressive therapy is considered to be a significant risk factor in the 60 61 development of a malignancy following SOT as it may lead to the activation of oncogenic viruses¹¹, dysfunction of DNA repair¹², and other immune-mediated mechanisms.¹³ Prior 62 63 studies have assessed the risk of malignancy across different organ types of transplantation, while others have investigated immunosuppressive regimens on the risk 64 of malignancy. However, no study has assessed the risk of malignancy across all organ 65 66 types with respect to immunosuppression. This study aims to identify potential risk factors associated with developing malignancy across all SOT types. Understanding the 67 malignancy risks associated with immunosuppressive medications across all organ 68

transplant types may lead to better informed patients and clinicians, allowing for themaintenance of graft function while limiting associated morbidity and mortality.

71

72 2 Methods

73 <u>2.1 Study design and data collection</u>

74 This is an IRB-approved, retrospective cohort study from three academic hospitals in the greater Chicago area – Lovola University Medical Center, Gottlieb Memorial Hospital, and 75 MacNeal Hospital. The electronic health record (EHR) software (Epic Systems; Verona, 76 WI) was gueried from January 1, 2000 to March 10, 2021. SOT and malignancies were 77 78 identified using a complete list of international classification of diseases (ICD) codes from 79 the 9th and 10th revision. The date of SOT and diagnosis of malignancy was defined as 80 the first instance an ICD code appeared in a patient's medical record. To ease in subsequent analysis, similar ICD-9 and ICD-10 diagnoses were grouped together into 81 nominal variables. The histological evaluation of each malignancy was not captured within 82 83 the ICD codes of this dataset. A complete list of medications and patient demographics, including age, sex, race, ethnicity, zip-code, and preferred language were also gueried 84 from the EHR. Patients under the age of 18 were not included in this study. 85

86

87 <u>2.2 Statistics</u>

A two-sided t-test was calculated to assess differences in numerical variables. Chisquared was used to assess differences in proportions. Pearson's r was used to assess for correlation between dichotomous variables. Loess smoothing was used to assess trends overtime.¹⁴ For time-to-event analysis, patients were censored when diagnosed

4

92 with a malignancy, or the last time a medication was taken, representing the last time of 93 contact with the study center or death. For each patient, every transplant and new malignancy diagnosis represented a new observation within the data frame. Gray's test 94 was used for the competing risk analysis.¹⁵ Immunosuppressive medications were 95 required to be taken for at least one day. Multivariable regression was performed using 96 Cox proportional hazard with time to malignancy as the dependent variable. Independent 97 variables included age at transplant, race, sex, immunosuppressive medications, and 98 transplanted organ. Statistical significance was defined as p-value < 0.05 and was 99 adjusted with a Bonferroni correction.¹⁶ 100

101

102 <u>2.3 Machine learning</u>

Variable importance calculations were performed as previously described.¹⁷ Categorical 103 104 variables with a frequency of less than 10% were grouped into an "other" category. 105 Nominal variables were one-hot encoded and numerical variables were normalized to 106 have a standard deviation of one with a mean of zero. The complete dataset was then bootstrap resampled 10 times and stratified by subsequent malignancy. A random forest 107 model was then fit across a variety of hyperparameters within a Latin hypercube of size 108 25.¹⁸ Gini impurity values were calculated to provide robust assessment of variable 109 importance.19 110

111

112 <u>2.4 Analysis code</u>

113 All analysis was performed with R programming language v.4.0.3.²⁰ using the 114 'tidyverse,'²¹ 'tidymodels,'²² 'lubridate,'²³ 'funneljoin,'²⁴ 'ggridges,'²⁵ 'surival,'²⁶ 'janitor,'²⁷

5

'wesanderson,'²⁸ 'ochRe,'²⁹ 'scales,'³⁰ 'vip,'³¹ 'resample,'³² 'corrplot,'³³ and 'tidycmprsk'³⁴
packages.

- 117
- 118 3 Results
- 119 <u>3.1 Transplant recipient descriptive statistics</u>

120 Overall, there were 5,591 unique patients who received a SOT during the gueried time 121 period, comprising six different organ types and 6,142 transplanted organs (Figure 1A). 122 Kidney transplants (n = 2.986) were the most common, followed by liver (n = 1.298), lung (n = 1,024), heart (n = 723), pancreas (n = 106), and intestine (n = 5) (Figure 1A). The 123 124 median age of a transplant recipient was 54 years with a range of 18-91 years 125 (Supplementary Figure 1A). 5,093 people received one SOT, 448 received two organs, 126 47 received three organs, and three received four organs (**Supplementary Figure 1B**). 127 64% of individuals to receive a transplant self-identified as White, while the next most common racial demographic was Black at 17% (Supplementary Figure 1C). White and 128 129 Asian transplant recipients were the oldest demographic to receive an organ at a median age of 56 years (Figure 1B). These two groups were statistically older than other minority 130 131 groups, including Black (52 years), Hispanic (50 years), and multi-racial (40 years) 132 (Figure 1B). The median age of transplantation was highest in lung (58 years), heart (58 years), and liver (59 years) transplantation (Figure 1C). Overall, 39% of transplant 133 134 recipients were women. With the exception of intestine, SOT was more common in men 135 than in women (**Figure 1D**). Since the beginning of this study, the number of SOT across time was increasing (Figure 1E). Loess smoothing showed a trend towards women 136 137 becoming less likely to receive SOT when compared to men (Figure 1F).

1	2	Q
1		0

139 <u>3.2 Subsequent malignancy descriptive statistics</u>

Of those that received a SOT, there were 517 (8.25%) malignancies identified after 140 141 transplantation. Skin cancer was the predominant malignancy across SOT recipients (n = 273), followed by lymphoma (n = 40), and kidney (n = 30) (**Figure 2A**). In liver and 142 143 kidney transplant recipients, subsequent liver and kidney malignancies represent the 144 largest proportional increase from baseline rates, respectively (Figure 2A). Liver cancer 145 was the earliest malignancy to present following SOT at an average of 351 days (Figure **2B**). The median presentation of skin cancer was 1,073 days, breast cancer at 1,109 146 days, and lymphoma at 1,123 days (**Figure 2B**). Leukemia (n = 12) was the malignancy 147 with the longest post-transplant latency time to presentation at just under five years (1,735 148 149 days) (Figure 2B). 14% of White transplant recipients were diagnosed with a malignancy 150 after SOT; Hispanic and Black individuals were diagnosed at 9% and 7%, respectively 151 (Figure 2C) Of the 249 Asian patients who received SOT, only four (1.6%) developed a 152 subsequent malignancy (Figure 2C). Lung transplant recipients who developed a subsequent malignancy were significantly younger than those who did not (p = 0.048) 153 (Figure 2D). No other SOT recipient group had a significant difference in subsequent 154 155 malignancies based on the age of transplantation (Figure 2D).

156

157 <u>3.3 Immunosuppression and development of malignancy</u>

158 The most common immunosuppressive medications used were mycophenolate, and 159 tacrolimus (**Supplementary Figure 2A**). The use of these medications increased 160 throughout the study duration (**Supplementary Figure 2B**). Cyclosporine and sirolimus

161 represent the largest proportion of immunosuppressive medications utilized in heart 162 transplant recipients, at 12% and 10%, respectively (Figure 3A). Azathioprine was most commonly used in lung transplant recipients at 33% and 91% of liver transplant recipients 163 164 received tacrolimus (Figure 3A). Tacrolimus and mycophenolate (phi coefficient 0.36) were the drugs most commonly used in the same patients, whereas tacrolimus and 165 166 cyclosporine (phi coefficient -0.36) were most rarely used together (Supplementary 167 Figure 3). Upon fitting a random forest machine learning (ML) model to assess variable 168 importance on the development of malignancy, age at transplantation was the most predictive variable followed by the total number of immunosuppressive medications a 169 patient has received (Figure 3B). The immunosuppressive medication with the strongest 170 171 association with post-transplant malignancy was sirolimus, followed by azathioprine and 172 tacrolimus (Figure 3B).

173

174 Heart and lung transplant recipients have a high cumulative incidence of subsequent 175 malignancy in our study (Figure 3C). Within 30 months post-transplant, 8.5% of heart and 8.7% of lung transplant recipients had a subsequent diagnosis of cancer 176 (Supplementary Figure 4). At five years, this number increased to 16% and 17% for 177 178 heart and lung transplant recipients, respectively (Supplementary Figure 4). Cumulative incidence of subsequent malignancy was greatest in patients who received sirolimus, 179 180 azathioprine, and cyclosporine, whereas mycophenolate, and tacrolimus had a relatively 181 lower cumulative incidence (Figure 3D). Multivariate Cox proportional hazard analysis demonstrated an increased risk of malignancy with azathioprine (HR 1.86, 95% CI 1.51 182 183 -2.28, p < 0.001), and sirolimus (HR 2.07, 95% CI 1.71 -2.52, p < 0.001), whereas

184 patients who receive tacrolimus (HR 0.48, 95% CI 0.39 - 0.59, p < 0.001) were less likely 185 to be diagnosed with a subsequent malignancy (Figure 3E). The differences seen in the cumulative incidence analysis stratified by organ type did not persist when adjusted for 186 187 multiple variables, such as race and immunosuppressive medications (Figure 3E). There was no significant difference in the risk of subsequent malignancy between men and 188 189 women or the age in which someone received a SOT (Figure 3E). Black (HR 0.55, 95%) 190 CI 0.41 - 0.73, p < 0.001) and other non-White (HR 0.24, 95% CI 0.16 - 0.36, p < 0.001) 191 SOT recipients were less likely to develop a malignancy than White individuals (Figure 192 **3E**). However, there was no difference in the rates of non-cutaneous malignancies 193 between Black and White transplants recipients (**Supplementary Figure 5**).

194

195 4 Discussion

196 To our knowledge, this is the first study to investigate the role of immunosuppression in 197 the development of malignancy following transplantation across multiple organ types of 198 transplantation. Our data are consistent with other landmark studies. For example, skin cancer was the most common malignancy diagnosed after SOT in our cohort, followed 199 by lymphoma and kidney cancer.³⁵ In concordance with the largest study of cancer risk 200 201 in SOT recipients, our data demonstrated that the majority of liver cancer diagnoses occur 202 within the first year of transplantation and kidney cancer incidence was highest in kidney transplant recipients.⁵ 203

204

A recent population-based cohort study in Finland found increased incidence of cancer rates in heart and lung transplant recipients in comparison to kidney and liver transplant

recipients.³⁵ However, upon adjusting for immunosuppressive medications, we found no difference in the rates of malignancy between SOT groups, indicating the increased risk may be due to the medication. In liver transplant recipients, cumulative exposure to tacrolimus increased the risk of cancer.³⁶ This finding was not unsurprising and not in opposition to our data as we did not assess cumulative exposure to tacrolimus. However, our data demonstrated a lower risk of cancer in individuals who receive tacrolimus compared to other immunosuppressive medications.

214

In our study, azathioprine and sirolimus were associated with the highest risk of cancer 215 development. Azathioprine, an antagonist of purine metabolism, has long been 216 217 associated with the development of cancer in SOT, inflammatory bowel disease, multiple sclerosis, and rheumatoid arthritis.³⁷⁻⁴¹ However, the increased risk associated with 218 219 sirolimus was unexpected as prior studies have generally demonstrated decreased risk of cancer with sirolimus use.^{42,43} In kidney and heart transplant recipients, the transition 220 from a calcineurin inhibitor to sirolimus was associated with a lower risk of malignancy,44-221 ⁴⁶ likely due in part to the role mTOR plays in cell proliferation.⁴⁷ 222

223

ML algorithms are now being applied to a variety of SOT research questions.⁴⁸ To our knowledge, our study represents the first time that a ML model has been used to assess variable importance in determining which SOT recipients developed a malignancy. Random forest classification, a form of decision trees, is a highly flexible, interpretable, and accurate method of estimating non-linear relationships – an area where traditional statistics struggle.⁴⁹ In contrast to traditional statistical methods used in this analysis, our

10

ML model identified age at transplant as a highly predictive marker of subsequent malignancy diagnosis. However, not all results were dissimilar, as the ML model also identified sirolimus, tacrolimus, azathioprine, and cyclosporine as highly predictive variables.

234

235 There are a number of limitations to this study. First, there are likely discrepancies in data 236 entry, collection, and classification that may exist as this was a retrospective cohort study 237 based on ICD codes. The rates of malignancy are likely underestimated as we included 238 individuals who received transplants up to the study endpoint, and patients may be lost 239 to follow-up for a variety of reasons. In addition, the hospitals gueried in this study are 240 located in the greater Chicago area, and thus may not represent results from distinct 241 geographical regions across the United States or in other countries. Furthermore, we did 242 not account for the dose of immunosuppression or blood plasma level of these medications. We also did not control for any pre-transplant related criteria, including organ 243 244 ischemic time, viral studies, donor information, screening tests, or education level. This may confound some of the findings that we attribute to sociodemographic factors and 245 246 immunosuppressive medications. Lastly, our findings do not establish causality. Further 247 work will be focused on parsing the complex relationship of concomitant immunosuppression and medication changes that may affect risk of malignancy. With 248 249 greater numbers of SOT recipients, we may be able to associate subsequent malignancy 250 type with individual immunosuppressive regimens, allowing for personalized cancer screening recommendations with the goal of improving overall survival.⁵⁰ 251

252

11

253 Acknowledgements:

254 Many thanks to Susan Zelisko for querying the data from the EHR for subsequent

analysis.

256

- 257 Funding:
- 258 No funding sources were used for this research project.
- 259
- 260 **Disclosures**:

261 The authors of this manuscript have no conflicts of interest to disclose as described by

the American Journal of Transplantation.

263

264 **References:**

Rana A, Gruessner A, Agopian VG, et al. Survival benefit of solid-organ transplant
 in the United States. *JAMA Surg.* 2015. doi:10.1001/jamasurg.2014.2038

267 2. The U.S. Organ Procurement and Transplantation Network and the Scientific

268 Registry of Transplant Recipients. 2021.

269 https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/.

270 3. Ying T, Shi B, Kelly PJ, Pilmore H, Clayton PA, Chadban SJ. Death after kidney

transplantation: An analysis by era and time post-transplant. *J Am Soc Nephrol*.

- 272 2020. doi:10.1681/ASN.2020050566
- 273 4. Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the
- incidence of malignancy in recipients of different types of organ: A UK registry
- audit. Am J Transplant. 2010. doi:10.1111/j.1600-6143.2010.03181.x

- 5. Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of cancer risk among US
 solid organ transplant recipients. *JAMA*. 2011. doi:10.1001/jama.2011.1592
- 278 6. Faure S, Herrero A, Jung B, et al. Excessive alcohol consumption after liver
- transplantation impacts on long-term survival, whatever the primary indication. J
- 280 *Hepatol.* 2012. doi:10.1016/j.jhep.2012.03.014
- 281 7. Hussain Z, Yu M, Wozniak A, et al. Impact of donor smoking history on post heart
- 282 transplant outcomes: A propensity-matched analysis of ISHLT registry. *Clin*
- 283 *Transplant*. 2021. doi:10.1111/ctr.14127
- 8. Penn I. Malignant melanoma in organ allograft recipients. *Transplantation*. 1996.
- 285 doi:10.1097/00007890-199601270-00019
- 286 9. Sprangers B, Nair V, Launay-Vacher V, Riella L V., Jhaveri KD. Risk factors
- associated with post-kidney transplant malignancies: An article from the Cancer-
- 288 Kidney International Network. *Clin Kidney J.* 2018. doi:10.1093/ckj/sfx122
- 10. Stallone G, Infante B, Grandaliano G. Management and prevention of post-
- transplant malignancies in kidney transplant recipients. *Clin Kidney J.* 2015.
- 291 doi:10.1093/ckj/sfv054
- 11. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in
- 293 people with HIV/AIDS compared with immunosuppressed transplant recipients: a
- 294 meta-analysis. *Lancet*. 2007. doi:10.1016/S0140-6736(07)61050-2
- 295 12. O'Donovan P, Perrett CM, Zhang X, et al. Medicine: Azathioprine and UVA light
- 296 generate mutagenic oxidative DNA damage. *Science (80-)*. 2005.
- 297 doi:10.1126/science.1114233
- 13. Lipson EJ, Bagnasco SM, Moore J, et al. Tumor Regression and Allograft

- 299 Rejection after Administration of Anti–PD-1. *N Engl J Med.* 2016.
- 300 doi:10.1056/nejmc1509268
- 14. Press WH, Teukolsky SA. Savitzky-Golay Smoothing Filters. *Comput Phys.* 1990.
- 302 doi:10.1063/1.4822961
- 303 15. Gray BJ. A class of K-sample tests for comparing the cumulative incidence of a
 304 competing risk. *Ann Stat.* 1988.
- Benjamini Y. Discovering the false discovery rate. *J R Stat Soc Ser B Stat Methodol*. 2010. doi:10.1111/j.1467-9868.2010.00746.x
- 307 17. Shaw R, Lokshin AE, Miller MC, Messerlian-Lambert G, Moore RG. Stacking
- 308 Machine Learning Algorithms for Biomarker-Based Preoperative Diagnosis of a

309 Pelvic Mass. *Cancers (Basel)*. 2022. doi:10.3390/cancers14051291

- 18. McKay MD, Beckman RJ, Conover WJ. A Comparison of Three Methods for
- 311 Selecting Values of Input Variables in the Analysis of Output from a Computer

312 Code. *Technometrics*. 1979. doi:10.2307/1268522

- 19. Menze BH, Kelm BM, Masuch R, et al. A comparison of random forest and its Gini
- 314 importance with standard chemometric methods for the feature selection and
- 315 classification of spectral data. *BMC Bioinformatics*. 2009. doi:10.1186/1471-2105-
- 316 10-213
- 317 20. R Core Team. R: A language and environment for statistical computing. *R Found*318 *Stat Comput.* 2019.
- Wickham H, Averick M, Bryan J, et al. Welcome to the Tidyverse. *J Open Source Softw.* 2019. doi:10.21105/joss.01686
- 321 22. Kuhn M. Package 'tidymodels': Easily Install and Load the "Tidymodels"

- 322 Packages. Cran.
- 323 23. Grolemund G, Wickham H. Dates and times made easy with lubridate. J Stat
- 324 Softw. 2011. doi:10.18637/jss.v040.i03
- 325 24. Robinson E, Baker A, and Robinson D. funneljoin: Time-Based Joins to Analyze
- 326 Sequence of Events. 2019. https://cran.r-project.org/package=funneljoin.
- 327 25. Wilke C. ggridges: Ridgeline Plots in "ggplot2." 2020. https://cran.r-
- 328 project.org/package=ggridges.
- 329 26. Therneau TM. A Package for Survival Analysis in R. 2022. https://cran.r-
- 330 project.org/package=survival.
- 331 27. Firke S. janitor: Simple Tools for Examining and Cleaning Dirty Data. 2020.
- 332 https://cran.r-project.org/package=janitor.
- 28. Ram K, Wickham H. wesanderson: A Wes Anderson Palette Generator. 2018.
- 334 https://cran.r-project.org/package=wesanderson.
- 335 29. Allan A, Cook D, Gayler R, Kirk H, Peng R, Saber E. ochRe: Australia-Themed
- Color Palettes. 2022.
- 337 30. Wickham H, Seidel D. scales: Scale Functions for Visualization. 2022.
- 338 31. Greenwell BM, Boehmke BC. Variable Importance Plots—An Introduction to the
- vip Package. *R J*. 2020. doi:10.32614/rj-2020-013
- 340 32. Tim Hesterberg. resample: Resampling Functions. 2022. https://cran.r-
- 341 project.org/package=resample.
- 342 33. Taiyun Wei, Simko V. R package "corrplot": Visualization of a Correlation Matrix.
- 343 2017. https://github.com/taiyun/corrplot.
- 344 34. Sjoberg DD, Fei T. tidycmprsk: Competing Risks Estimation. 2022. https://cran.r-

345 project.org/package=tidycmprsk.

- 346 35. Friman TK, Jäämaa-Holmberg S, Åberg F, et al. Cancer risk and mortality after
- 347 solid organ transplantation: A population-based 30-year cohort study in Finland.
- 348 Int J Cancer. 2022. doi:10.1002/ijc.33934
- 349 36. Rodríguez-Perálvarez M, Colmenero J, González A, et al. Cumulative exposure to
- 350 tacrolimus and incidence of cancer after liver transplantation. *Am J Transplant*.
- 351 2022;22(6):1671-1682. doi:10.1111/ajt.17021
- 352 37. Jiyad Z, Olsen CM, Burke MT, Isbel NM, Green AC. Azathioprine and Risk of Skin
- 353 Cancer in Organ Transplant Recipients: Systematic Review and Meta-Analysis.
- 354 Am J Transplant. 2016. doi:10.1111/ajt.13863
- 355 38. Pasternak B, Svanström H, Schmiegelow K, Jess T, Hviid A. Use of azathioprine
- and the risk of cancer in inflammatory bowel disease. *Am J Epidemiol*. 2013.
- 357 doi:10.1093/aje/kws375
- 358 39. Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G. Risk of
- 359 cancer from azathioprine therapy in multiple sclerosis: A case-control study.
- 360 *Neurology*. 1996. doi:10.1212/WNL.46.6.1607
- 361 40. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE, Dickson M, Balkwill AM.
- 362 Long-term neoplasia risk after azathioprine treatment in inflammatory bowel
- 363 disease. *Lancet*. 1994. doi:10.1016/S0140-6736(94)92150-4
- 364 41. Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug
- 365 exposure in rheumatoid arthritis. *Arch Intern Med*. 2008.
- 366 doi:10.1001/archinternmed.2007.107
- 367 42. Karia PS, Azzi JR, Heher EC, Hills VM, Schmults CD. Association of sirolimus

- 368 use with risk for skin cancer in a mixed-organ cohort of solid-organ transplant
- 369 recipients with a history of cancer. *JAMA Dermatology*. 2016.
- 370 doi:10.1001/jamadermatol.2015.5548
- 43. Knoll GA, Kokolo MB, Mallick R, et al. Effect of sirolimus on malignancy and
- 372 survival after kidney transplantation: Systematic review and meta-analysis of
- individual patient data. *BMJ*. 2014. doi:10.1136/bmj.g6679
- 44. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's Sarcoma in Renal-
- 375 Transplant Recipients. *N Engl J Med*. 2005. doi:10.1056/nejmoa042831
- 45. Asleh R, Clavell AL, Pereira NL, et al. Incidence of Malignancies in Patients
- 377 Treated With Sirolimus Following Heart Transplantation. *J Am Coll Cardiol*. 2019.
- 378 doi:10.1016/j.jacc.2019.03.499
- 46. Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and Secondary Skin-Cancer
- 380 Prevention in Kidney Transplantation. *N Engl J Med*. 2012.
- 381 doi:10.1056/nejmoa1204166
- 47. Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. *J Chem Biol*. 2008.
- 383 doi:10.1007/s12154-008-0003-5
- 48. Gotlieb N, Azhie A, Sharma D, et al. The promise of machine learning
- applications in solid organ transplantation. *npj Digit Med*. 2022;5(1).
- 386 doi:10.1038/s41746-022-00637-2
- 387 49. Couronné R, Probst P, Boulesteix AL. Random forest versus logistic regression: A
- 388 large-scale benchmark experiment. *BMC Bioinformatics*. 2018.
- 389 doi:10.1186/s12859-018-2264-5
- 390 50. Dharia A, Boulet J, Sridhar VS, Kitchlu A. Cancer Screening in Solid Organ

- 391 Transplant Recipients: A Focus on Screening Liver, Lung, and Kidney Recipients
- for Cancers Related to the Transplanted Organ. *Transplantation*. 2022.
- 393 doi:10.1097/TP.000000000003773
- 394




Figure 1.

A) Bar plot of the overall number of solid organ transplants stratified by organ type. B) Boxplots of the age of solid organ transplant stratified by race C) Boxplots of the age of solid organ transplant grouped by organ type. D) Grouped bar plot of solid organ transplant types stratified by sex. Male is denoted by 'M' and Female is denoted by 'F.' E) Solid organ transplant recipients across time stratified by organ type. F) Dot plot showing the percent of women who received a solid organ transplant across the study time period. A loess smoothed line is overlayed.




Figure 2.

A) Stacked bar plot of subsequent malignancies by solid organ transplant type. B) Ridge plot of subsequent malignancies from time of transplant. C) Stacked bar plot of the proportion of subsequent malignancies stratified by race. True indicates the development of a subsequent malignancy. D) Boxplots of subsequent malignancies by age at transplant stratified by organ type.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.02.22283027; this version posted December 4, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.




Figure 3.

A) Stacked bar plot of immunosuppressive medications stratified by organ type. B) Boxplots of random forest Gini impurity values indicating variable importance in predicting malignancy following solid organ transplant. C) Subsequent malignancy cumulative incidence plot stratified by organ type. D) Subsequent malignancy cumulative incidence plot stratified by organ type. D) Subsequent malignancy cumulative incidence plot stratified by organ type. D) Subsequent malignancy cumulative incidence plot stratified by immunosuppressive medication. E) Forest plot of the multivariate Cox proportional hazard ratios. Black and Other Non-White hazard ratios are in comparison to White. Heart, liver, and lung are in comparison to kidney transplant recipients. P-values are adjusted with a Bonferroni correction factor.